Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.

Article  PubMed  PubMed Central  Google Scholar 

Scheltema NM, Gentile A, Lucion F, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5(10):e984–91.

Article  PubMed  PubMed Central  Google Scholar 

Simões EAF. The burden of respiratory syncytial virus lower respiratory tract disease in infants in the United States: a synthesis. J Infect Dis. 2022;226:S143–7.

Article  PubMed  PubMed Central  Google Scholar 

Korsten K, Adriaenssens N, Coenen S, et al. Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. Eur Respir J. 2021;57(4):2002688.

Article  PubMed  Google Scholar 

Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.

Article  CAS  PubMed  Google Scholar 

Miller AM, Varga SM. Fusing safety and efficacy: a maternal bivalent RSV prefusion F vaccine. Cell Rep Med. 2023;4(6): 101081.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biagi C, Dondi A, Scarpini S, et al. Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines (Basel). 2020;8(4):672.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swedish Orphan Biovitrum AB. SYNAGIS® (palivizumab) injection, for intramuscular use: US prescribing information. 1998. https://synagishcp.com/synagis.pdf. Accessed 5 Sep 2023.

Simões EAF, Center KJ, Tita ATN, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615–26.

Article  PubMed  Google Scholar 

Noble M, Khan RA, Walker B, et al. Respiratory syncytial virus-associated hospitalisation in children aged ≤5 years: a scoping review of literature from 2009 to 2021. ERJ Open Res. 2022;8(2):00593–2021.

Article  PubMed  PubMed Central  Google Scholar 

Buchwald AG, Graham BS, Traore A, et al. Respiratory Syncytial Virus (RSV) neutralizing antibodies at birth predict protection from RSV illness in infants in the first 3 months of life. Clin Infect Dis. 2021;73(11):e4421–7.

Article  PubMed  Google Scholar 

Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64.

Article  CAS  PubMed  Google Scholar 

McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmoele-Thoma B, Zareba AM, Jiang Q, et al. Vaccine efficacy in adults in a respiratory syncytial virus challenge study. N Engl J Med. 2022;386(25):2377–86.

Article  CAS  PubMed  Google Scholar 

US Food and Drug Administration. FDA approves first vaccine for pregnant individuals to prevent RSV in infants [media release]. 21 Aug 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants.

Pfizer. ABRYSVO™ (Respiratory Syncytial Virus Vaccine) solution for intramuscular injection: US prescribing information. 2023. https://labeling.pfizer.com/ShowLabeling.aspx?id=19589. Accessed 6 Sep 2023.

Pfizer. U.S. FDA approves ABRYSVO™, Pfizer’s vaccine for the prevention of respiratory syncytial virus (RSV) in older adults. [media release]. 31 May 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention.

Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77.

Article  CAS  PubMed  Google Scholar 

Centers for Disease Control and Prevention. CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth [media release]. 22 Sep 2023. https://www.cdc.gov/media/releases/2023/p0922-RSV-maternal-vaccine.html.

The American College of Obstetricians and Gynecologists. Maternal respiratory syncytial virus vaccination: practice advisory. 2023. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/09/maternal-respiratory-syncytial-virus-vaccination#:~:text=The%20American%20College%20of%20Obstetricians%20and%20Gynecologists%20(ACOG)%20recommends%20a,respiratory%20tract%20infection%20in%20infants. Accessed 2 Oct 2023.

European Medicines Agency. Abrysvo powder and solvent for solution for injection [respiratory syncytial virus vaccine (bivalent, recombinant)]: EU summary of product characteristics. 2023. https://www.ema.europa.eu/en/documents/product-information/abrysvo-epar-product-information_en.pdf. Accessed 26 Sep 2023.

Pfizer. European Commission approves Pfizer’s ABRYSVO™ to help protect infants through maternal immunization and older adults from RSV. [media release]. 24 Aug 2023. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-abrysvotm-help-protect.

Walsh EE, Falsey AR, Scott DA, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022;225(8):1357–66.

Article  CAS  PubMed  Google Scholar 

Peterson JT, Zareba AM, Fitz-Patrick D, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine. J Infect Dis. 2022;225(12):2077–86.

Article  CAS  PubMed  Google Scholar